Research & Development

Can BRTX-100 Revolutionize Treatment for Chronic Lumbar Disc Disease?
Research & Development Can BRTX-100 Revolutionize Treatment for Chronic Lumbar Disc Disease?

The recent FDA Fast Track designation for BioRestorative Therapies' BRTX-100 program marks a significant milestone in the treatment of chronic lumbar disc disease (cLDD). Given the debilitating nature of cLDD and its prevalence among middle-aged Americans, this development has sparked considerable

Revolutionary 3D Imaging Breakthrough Enhances Medical Diagnostics
Research & Development Revolutionary 3D Imaging Breakthrough Enhances Medical Diagnostics

A groundbreaking advancement in medical imaging technology developed by researchers at the University of Houston promises to significantly transform medical diagnostics. This innovative development centers around a sophisticated 3D imaging system that offers enhanced precision and efficiency

Novel Ce6-GFFY Photosensitizer Shows Promise for Colorectal Cancer Therapy
Research & Development Novel Ce6-GFFY Photosensitizer Shows Promise for Colorectal Cancer Therapy

Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, primarily due to its high potential for metastasis and the related challenges in treatment. These challenges often include drug toxicity, tumor recurrence, and development of drug resistance due to genetic

Advancements in Targeted Therapies for PIK3CA-Mutated Cancers
Research & Development Advancements in Targeted Therapies for PIK3CA-Mutated Cancers

Recent scientific advancements have shed new light on the implications of PIK3CA mutations in cancer treatment, prompting significant interest in developing targeted therapies to enhance drug efficacy while mitigating adverse effects. The PIK3CA gene, which encodes the p110α subunit of

Can Ivonescimab and Pfizer's ADCs Transform Cancer Treatment?
Research & Development Can Ivonescimab and Pfizer's ADCs Transform Cancer Treatment?

Key players in the pharmaceutical landscape, Summit Therapeutics and Pfizer, are embarking on a noteworthy collaboration to test out Summit’s experimental immunotherapy, ivonescimab, combined with Pfizer’s sophisticated antibody-drug conjugates (ADCs) in upcoming clinical trials targeting specific

Research Priorities Set to Improve Appendiceal Cancer Understanding and Treatment
Research & Development Research Priorities Set to Improve Appendiceal Cancer Understanding and Treatment

Appendiceal cancer, a rare malignancy, presents significant challenges due to the lack of standardized screening guidelines, identifiable risk factors, and a common tumor classification system. These hurdles often result in delayed diagnoses and poor prognoses for patients. The estimated annual

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later